In a significant move aimed at increasing global patient access to medications, the U.S. Food and Drug Administration (FDA) has launched the Global Reliance Disclosure Program (GRDP). Announced on November 17, 2026, this initiative is designed to optimize how drug approval decisions by the FDA are used by health authorities worldwide. By facilitating faster access to innovative therapies, the GRDP reinforces the FDA's position as a global leader in drug regulation.
The GRDP allows the FDA to share minimally redacted approval packages with international partners. This includes comprehensive scientific and regulatory assessments, enabling foreign regulatory authorities to rely on the FDA’s thorough evaluations instead of conducting potentially redundant assessments. This mechanism is intended to streamline processes and reinforce sovereignty in regulatory decisions, thereby accelerating patient access to drugs in various countries.
Grace Graham, FDA’s Deputy Commissioner for Policy, Legislation, and International Affairs, stated, "The GRDP is a prime example of America First policies improving public health worldwide." By leveraging the FDA’s rigorously conducted reviews, applicants can foster quicker access to medicines outside the United States. This shift is particularly significant for applicants whose products will be evaluated in global health contexts.
The program saw its pilot launch on October 30, 2026, with the tentative approval of lenacapavir, a drug that plays a critical role in the prevention and treatment of HIV. Given the ongoing global health crisis related to HIV/AIDS, the selection of this drug serves as a meaningful start for the GRDP, marking its commitment to combat health inequities on a global scale.
Looking ahead, the FDA plans to broaden the program in January 2027, allowing it to encompass all novel drugs and biologics, specifically New Molecular Entity New Drug Applications as well as 351(a) Biologics License Applications. This expansion is expected to significantly widen the program’s impact, providing diverse new treatments to international patients. Additionally, the FDA is preparing to introduce a pathway aimed at allowing applicants expedited access to their minimally redacted application packages for approved drugs. This change will likely facilitate access to therapies already deemed safe and effective in the U.S.
To enroll in the GRDP and receive minimally redacted approval packages, applicants must express their interest within 10 calendar days following their drug's approval. This participation request must also confirm that the application is intended for submission to a foreign health authority. The FDA emphasizes that requests for packages unrelated to regulatory applications will not be accepted under this program but can be made via the Freedom of Information Act (FOIA).
Mark Abdoo, Associate Commissioner for Global Policy and Strategy, indicated that the GRDP represents a forward-looking vision of regulatory collaboration. By sharing expertise and elevating global health standards, the FDA aims to eliminate the time lag often experienced in lower-resource settings following U.S. drug approvals. In many instances, patients in developing countries may face lengthy delays as their local authorities conduct independent reviews, often leading to critical gaps in access to vital medications.
The GRDP not only enhances individual product accessibility but also contributes to global health security. It promotes harmonized regulatory decisions, reducing the potential for inconsistent standards across different markets. This uniformity ensures that high-quality therapeutic options are available to patients universally, including in the United States.
As the FDA embarks on this ambitious program, ongoing evaluations will be essential to identify further opportunities for enhancing patient access and addressing regulatory challenges that persist on the global stage. Specific metrics to assess the success and effectiveness of the GRDP will be crucial for its continued adaptation and expansion, ensuring that it meets the needs of patients and healthcare systems worldwide.
Media: 202-690-6343 | Consumer: 888-INFO-FDA The FDA safeguards public health through rigorous evaluation processes for drugs, biologics, and medical devices.